https://www.mdpi.com/2673-8937/6/2/15
Matsuoka, T.; Kobayashi, N. Cardiovascular Event Surveillance Following High-Dose Intravenous Mesenchymal Stem Cell Therapy: A Single-Center Real-World Observational Study. Int. J. Transl. Med. 2026, 6, 15. https://doi.org/10.3390/ijtm6020015
This longitudinal study retrospectively evaluated MACCE (major adverse cardiac and cerebrovascular events—the incidence of life-threatening conditions such as myocardial infarction and ischemic stroke) over a rigorous 10-year follow-up period, meticulously comparing three distinct cohorts: the general Asian population (represented by the green dotted line), a patient group administered 100 million stem cells (the yellow line), and a patient group administered a high-dose of 1 billion stem cells (the blue line). The vertical axis of the graph illustrates the "MACCE-free rate," indicating the definitive percentage of patients who successfully remained free from these serious, life-threatening illnesses, while the horizontal axis tracks the precise number of years elapsed over the decade.
While each curve naturally declines over the decade, the data elegantly demonstrates that at the 10-year milestone, the high-dose 1 billion stem cell cohort exhibits a significantly lower incidence of serious, life-threatening illness compared to the standard 100 million stem cell cohort.
HELENE Clinic’s defining hallmark has been our ability to safely deliver exceptionally high cell counts—a direct testament to our world-class technical expertise. With the publication of this landmark paper, it is now unequivocally proven that this translates into profound clinical benefits: over the long term, a high-dose stem cell regimen significantly drives down the incidence of life-threatening illnesses, decisively promoting true longevity and a healthier life.
One of the inherent complexities of stem cell therapy is that their therapeutic impact spans multiple biological systems, which traditionally makes establishing unified scientific evidence of their clinical efficacy exceptionally challenging. To be completely candid, it is far simpler to track and demonstrate targeted therapeutic outcomes for a single, isolated condition, such as "XX disease."
Yet, the true epicentre of global medical research has definitively shifted toward advanced longevity and anti-aging science, and I am firmly convinced that the absolute vanguard of this frontier lies in unleashing the profound "longevity effects of stem cells." It is my sincerest hope that this newly accepted paper will serve as a vital piece of the puzzle, contributing meaningfully to the ongoing global scientific verification of these life-changing breakthroughs.
